金融公司调整了Regeneron(一家75B的毒品公司)的股权,Keudell的股权增加了43%。 Financial firms adjusted stakes in Regeneron, a $75B drug company, with Keudell increasing holdings by 43%.

Keudell Morrison财富管理公司和其他金融公司在第四季度调整了 Regeneron制药公司股票的持有量。 Keudell Morrison Wealth Management and other financial firms adjusted their holdings in Regeneron Pharmaceuticals stock in the fourth quarter. Keudell的股份增加了43%,而Busey Bank的股份略有减少。 Keudell increased its stake by 43%, while Busey Bank slightly reduced its holdings. Regeneron的市场上限为75.06亿美元,开发各种疾病的药品,包括EYLEA注射眼疾药物。 Regeneron, with a market cap of $75.06 billion, develops medicines for various diseases, including the EYLEA injection for eye conditions. 分析师对股票的评级是“机动购买”,目标价格为1 004.57美元。 Analysts have a "Moderate Buy" rating on the stock with a target price of $1,004.57.